Archive: Ablating CAR T Cells for AML with Alemtuzumab: CIPO2015
417 views · Published 16 October 2015 · 15:49 · Indexed 28 October 2026
Channel: UW Video · 2015 · Education
Dr. Sarah K. Tasian of The Children’s Hospital of Philadelphia speaks at the 4th International Conference on Immunotherapy in Pediatric Oncology (CIPO2015), hosted by Seattle Children’s Research Institute. Dr. Tasian discusses how long-term persistence of acute myeloid leukemia (AML) antigen-redirected chimeric antigen receptor T cells may lead to undesirable on target/off tumor toxicity. She explains how the development of effective T cell termination strategies may increase the potential therapeutic window of CAR T cell immunotherapy for patients with AML. Sarah K. Tasian, MD, Assistant Professor of Pediatrics, Division of Oncology, The Children’s Hospital of Philadelphia 09/26/2015 http://www.seattlechildrens.org/research/ AND http://www.seattlechildrens.org/research/childhood-cancer/CIPO-2015/ http://uwtv.org The University of Washington is committed to ensuring digital accessibility in our services, programs, and activities. If you encounter accessibility barriers using videos found on this channel, please contact UW Video at uwvideo [at] uw [dot] edu.
More from this channel
-
54:45
Archive: Usable Privacy and Security: Protecting People from Online Phishing Scams
-
58:27
Archive: Technology for Long-Term Care: Scaling Elder Care to the Next Billion
-
53:34
Archive: Closing the Innovation Gap
-
52:34
Archive: Hardness Amplification by Repetition
-
54:57
Archive: Network Coded Wireless Architecture
-
56:48
Archive: Computer Science Research for Global Development
-
58:16
Archive: Thinking Historically about Thinking Historically: Identity Politics to Ethical Action
-
27:18
Archive: Eastside Specialty Center: Coordination of Care